Trial Profile
A Phase 1, Open-label, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of TAK-385 Alone in Hormone Treatment- naïve Japanese Patients With Non-metastatic Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Relugolix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Takeda
- 01 Jun 2017 Planned number of patients changed from 30 to 43.
- 01 Jun 2017 Status changed from active, no longer recruiting to completed.
- 15 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.